



1638

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of SONG, et al.

Serial No.: 09/896,720
Date Filed: June 29, 2001
For: UBIQUITIN LIGASE

Examiner: KRUSE, DAVID H.
Group: 1638

RECEIVED


NOV 06 2002

TECH CENTER 1600/2900

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents, Washington, DC 20231 on

October 30, 2002.


Stanley A. Kim, Ph.D., Esq. Reg. No. 42,730

TRANSMITTAL LETTER

Commissioner for Patents
Washington, DC 20231

Sir:

Please find enclosed for filing the following:

X Response; and


X One postcard.

Although no fee is believed due, please charge any underpayment to Deposit Account No. 50-0951. This letter is submitted in duplicate.

Date: October 30, 2002

Docket No. 5853-173

Respectfully submitted,


Gregory A. Nelson, Esq.
Registration No. 30,577
Stanley A. Kim, Ph.D., Esq.
Registration No. 42,730
AKERMAN SENTERFITT
222 Lakeview Avenue, Suite 400
West Palm Beach, FL 33401
Telephone: (561) 653-5000



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of SONG, et al.

Application No.: 09/896,720

Examiner: KRUSE, DAVID H.

Date Filed: June 29, 2001

Group: 1638

For: UBIQUITIN LIGASE

#9/2100
TECH CENTER 1600/2900
NOV 06 2002
RECEIVED

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231, on October 30, 2002.

Reg. No. 42,730

Stanley A. Kim, Ph.D., Esq.

RESPONSE

Commissioner for Patents
Washington, DC 20231

Sir:

This response is in reply to the office action mailed October 1, 2002 (the "Office Action").

REMARKS

Election/Restriction

In the above-identified Office Action, the Examiner issued a restriction requirement and required election of one of the following groups under 35 U.S.C. § 121:

- I: Claims 1-7, 19 and 20, drawn to a purified nucleic acid encoding a XB3 protein or an XB3-like protein, a vector comprising said nucleic acid, a cell comprising said nucleic acid and a method of modulating disease resistance in a plant cell or seed by transforming a plant cell with said nucleic acid, classified in class 536, subclass 23.6, for example.
- II: Claims 8-13, drawn to a purified XB3-like protein and an antibody directed thereto, classified in class 530, subclass 370, for example.